Risk in every deal that it doesn't go through. Regulators will have a field day, especially if they make you sell the crown jewels to satisfy conditions. Don't try to be a hero. Take your money and run. Better opportunities elsewhere.

Interesting, good company, profitable. A bit rich now. He was worried about private labels taking market share. Could buy it on the right dip. He's looking at it.

He's buying it under $4. Tremendous value. Underlying tech businesses are growing. Thinks they'll surprise the market with good organic growth. They'll have their day in the sun and capture the market's attention. Helps professionals become more efficient. Unique partnerships, especially one with LTC homes.

Great assets, great business. Results have held steady through the pandemic. Afterwards, lots of high margin areas should start growing again. Reasonably priced. Hang on or buy more. If it's taken out by the major shareholder, it will be at a significantly higher price.

Great, stable, recession-proof business. Unique management team. Based in the US. Great consolidation opportunities. Nice safe holding, potential for long-term, steady growth. Great asset class.

Tremendously undervalued. Streamlining is coming along great. Improved corporate governance with non-family CEO. More selective about projects, with no more low margins. Share price moving up.

(A Top Pick Jun 16/20, Up 34%) One of his biggest positions. Rose during pandemic. Unaffected by lockdowns. Several large, accretive acquisitions, making them the largest player in Canada at 20% of the institutional pharmacy market. Huge tailwinds with the seniors demographic. Focused strategy, well managed, more consolidation to come, plus organic growth.